Trial Profile
A phase II trial of Neoadjuvant and adjuvant chemotherapy with Gemcitabine and TS-1 combination for patients with locally advanced pancreatic cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Jun 2018
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Ductal carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms CAP-003
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 11 May 2011 New trial record